European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line (1L) therapy for EGFR mutation-positive (EGFRm) advanced/metastatic non-small cell lung cancer (NSCLC). OBJECTIVE: Our objective was to describe real-world treatment patterns and T790M...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Riyaz, Girard, Nicolas, Nagar, Saurabh P., Griesinger, Frank, Roeper, Julia, Davis, Keith L., Karimi, Parisa, Sawyer, William, Yu, Ning, Taylor, Aliki, Feliciano, Josephine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605952/
https://www.ncbi.nlm.nih.gov/pubmed/34533784
http://dx.doi.org/10.1007/s40801-021-00261-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605952/
https://www.ncbi.nlm.nih.gov/pubmed/34533784
http://dx.doi.org/10.1007/s40801-021-00261-8

Ejemplares similares